The Valley Desk

ArticleCancer chemotherapy and pharmacologyPublished

Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL)

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Cancer chemotherapy and pharmacology
Published
Subject terms
Humans; Piperidines; Pyrazoles; Pyrimidines; Adenine; Protein Kinase Inhibitors; Dose-Response Relationship, Drug; Models, Biological; Aged; Middle Aged; Female; Male
PubMed ID
40019563
PubMed Central ID
PMC11870975
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal